Camidge DR, Morgensztern D, Heist RS, Barve M, et al. Phase 1 Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients With Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res 2021 Aug 23. pii: 1078-0432.CCR-21-0765.
PMID: 34426443